Abstract
RET-fusions are a known cause of acquired osimertinib resistance in patients with advanced NSCLC. Herein we describe the case of a patient who developed resistance to osimertinib, via acquisition of a novel CGN-RET fusion mutation. She had a favorable response to treatment with RET-targeting TKI selpercatinib, in combination with osimertinib.
Author supplied keywords
Cite
CITATION STYLE
Mirshahidi, H., Kwon, S. M. S., Romagnolo, A., Park, K., & Hagele, A. (2023). Advanced EGFR-mutant NCSLC resistant to osimertinib therapy as a result of a novel CGN-RET fusion mutation with favorable response to combined osimertinib and selpercaptinib, case report. Current Problems in Cancer: Case Reports, 11. https://doi.org/10.1016/j.cpccr.2023.100246
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
